Balance Sheet
Cash Flow Statement
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginInterest Coverage RatioInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on SalesTimes Interest Earned

Ensysce Biosciences (ENSCW) FCF Margin (2020 - 2025)

Historic FCF Margin for Ensysce Biosciences (ENSCW) over the last 6 years, with Q3 2025 value amounting to 378.46%.

  • Ensysce Biosciences' FCF Margin fell 3486100.0% to 378.46% in Q3 2025 from the same period last year, while for Sep 2025 it was 156.97%, marking a year-over-year increase of 362000.0%. This contributed to the annual value of 144.0% for FY2024, which is 3392900.0% up from last year.
  • As of Q3 2025, Ensysce Biosciences' FCF Margin stood at 378.46%, which was down 3486100.0% from 197.37% recorded in Q2 2025.
  • In the past 5 years, Ensysce Biosciences' FCF Margin registered a high of 29.77% during Q2 2021, and its lowest value of 2403.54% during Q3 2022.
  • Its 5-year average for FCF Margin is 593.05%, with a median of 349.86% in 2023.
  • As far as peak fluctuations go, Ensysce Biosciences' FCF Margin tumbled by -21105300bps in 2022, and later surged by 18838400bps in 2023.
  • Over the past 5 years, Ensysce Biosciences' FCF Margin (Quarter) stood at 230.41% in 2021, then grew by 0bps to 229.91% in 2022, then plummeted by -52bps to 349.86% in 2023, then surged by 83bps to 58.61% in 2024, then plummeted by -546bps to 378.46% in 2025.
  • Its last three reported values are 378.46% in Q3 2025, 197.37% for Q2 2025, and 129.37% during Q1 2025.